

# QUIZ

## 13/01/2025

Dr Kishore S Dharan  
Consultant Nephrologist  
MOSC Medical College, Kolenchery

# All are true about Tirzepatide except

1. Carries highest glycemic efficacy among all Incretin based agents
2. No added clinical benefit when combined with DPP IV inhibitors
3. Higher weight loss in diabetic obese compared to nondiabetics
4. FDA approved pharmacotherapy for Obstructive sleep apnea

**Answer :** 3. Higher weight loss in diabetic obese compared to nondiabetics

## **TIRZEPATIDE**

Dual GLP-1 and GIP Receptor agonist

Decreases HbA1c by 2.07%

Activation of both receptors – greater glycemic control

No added clinical benefit with DPP IV inhibitors

**SURMOUNT TRIAL** – 18-20% weight reduction in non diabetic obese, while obese diabetics had 12-14% weight reduction

**SURMOUNT OSA Trial - Tirzepatide** reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes

FDA approved Tirzepatide as drug for moderate to severe OSA in Dec 2024

# WINNER

Dr. Saravana Balaji  
2nd year DM resident  
Madras Medical College,  
Chennai



## Question No: 2

Of the following drugs in trials for diabetes/obesity/cardiometabolic Renal outcomes, which is not a GLP1 Agonist?

1. Retatrutide
2. Cagrilintide
3. Orfoglipron
4. Lixisenatide

## Ans: 2 ; Cagrilintide

- **Retatrutide** – novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors
- **Cagrilintide** -a dual amylin and calcitonin receptor agonist; used along with Semaglutide as CagriSema
- **Orfoglipron and Danuglipron** are non peptide partial GLP-1RA- can be given orally without respect to food alike
- **Lixisenatide** – early GLP1RA – daily s/c , short acting agent

# WINNER

Dr. Saravana Balaji  
2nd year DM resident  
Madras Medical College,  
Chennai

